New insights into the paradox between smoking and the risk of SARS-CoV-2 infection (COVID-19): Insufficient evidence for a causal association

Author:

Kramer Iris1ORCID,Zhu Yinjie2ORCID,Van Westen-Lagerweij Naomi A.13,Dekker Louise H.24,Mierau Jochen O.567,Croes Esther A.1

Affiliation:

1. The Netherlands Expertise Centre for Tobacco Control, Trimbos Institute, The Netherlands

2. Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Centre Groningen, The Netherlands

3. Department of Health Promotion, Maastricht University, The Netherlands

4. National Institute for Public Health and the Environment (RIVM), The Netherlands

5. Department of Economics, Econometrics & Finance, Faculty of Economics and Business, University of Groningen, The Netherlands

6. Lifelines Cohort Study and Biobank, The Netherlands

7. Team Strategy & External Relations, University of Groningen, University Medical Centre The Netherlands

Abstract

Aims: Previous studies have reported a ‘smoker’s paradox’, where people who smoke appear to be protected against Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV-2) infection (COVID-19). This conflicts with well-established evidence that people who smoke are generally more vulnerable to respiratory infections. In this study, we aimed to validate the association between smoking and SARS-CoV-2 infection in a general Dutch population, and to evaluate the evidence underlying the possible causal relationship between smoking and SARS-CoV-2 infection by applying a modern adaptation of the Bradford Hill criteria. Methods: In total, 57,833 participants from the Lifelines Cohort Study were included in the analysis. Smoking status, including never smoker, current smoker, and former smoker, was derived from the Lifelines general assessment between 2014 and 2017, while SARS-CoV-2 infection status was derived from an additional COVID-19 questionnaire from 2021 to 2022. Logistic regressions were used for the association between smoking status and infection status. The adapted Bradford Hill’s criteria, including the strength of association (including an analysis of plausible confounding), plausibility, temporality and study design suitability, were applied to evaluate the existing literature. Results: We found, compared with never smokers, an increased risk of SARS-CoV-2 infection for former smokers (odds ratio (OR)=1.07, 95% confidence interval (CI)=1.01–1.13), but a reduced risk for current smokers (OR=0.85, 95% CI=0.79–0.92), after adjusting for several relevant covariates. However, we discerned a possible explanation of the smoker’s paradox since we observed that current smokers were more likely to be non-responders to the COVID-19 questions and, more importantly, these non-responders were more likely to have other established risk factors for SARS-CoV-2 infection. Conclusions: There is insufficient evidence to suggest that smoking protects against SARS-CoV-2 infection. According to the adapted Bradford Hill’s criteria, we observed a high inconsistency between study results, a high possibility for residual confounding and no clear evidence for biological plausibility. Future studies should include linkage with the confirmed testing results from national healthcare registries to mitigate avoidable bias.

Funder

Ministerie van Volksgezondheid, Welzijn en Sport

Provinces in the North of the Netherlands

Rijksuniversiteit Groningen

Universitair Medisch Centrum Groningen

Ministerie van Economische Zaken en Klimaat

Publisher

SAGE Publications

Reference38 articles.

1. U.S. Department of Health and Human Services. How tobacco smoke causes disease: The biology and behavioral basis for smoking-attributable disease. 2010, https://www.ncbi.nlm.nih.gov/books/NBK53017/ (accessed 1 July 2023)

2. Tobacco product use and the risks of SARS-CoV-2 infection and COVID-19: current understanding and recommendations for future research

3. Are smokers protected against SARS-CoV-2 infection (COVID-19)? The origins of the myth

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3